Protego Biopharma is a San Diego-based biotech company focused on developing small-molecule drugs that target protein misfolding pathways. By reprogramming cellular processes to restore proper protein function, Protego aims to treat rare and systemic diseases with precision and improved patient outcomes.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/08/25 | $130,000,000 | Series B |
Digitalis Ventures DROIA Ventures Forbion Capital Partners  Lightspeed Venture Partners MPM BioImpact Novartis Venture Funds Omega Funds Scripps Research Vida Ventures YK Bioventures | undisclosed |
